Business   

Novartis gets EMR approval for Glivec

MUMBAI NOV. 12. Novartis India said today it has become the first pharmaceutical company in the country to be granted exclusive marketing rights (EMR) for Glivec, a drug used in treatment of cancer, by the Controller General of Patents and Trademarks of India.

"This is a positive sign to the international community that India is progressing towards meeting all its obligations under TRIPS,'' Novartis India Vice-Chairman and Managing Director, Ranjit Shahani, told newspersons here today.

Glivec is one of the oncology drugs that validate rational drug design based on an understanding of how some cancer cells work. — PTI

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary |

Stories in this Section

• Industry grows at 6.5 p.c. in Sept.
• Branding India abroad
• Disinvestment options to meet revenue target
• CBI raids broker, SBI MF, UTI officials
• Two directors of Silverline resign
• Equities lose early gains
• ECB norms modified
• 3 held for taking bribes from IBM Corp.
• Rupee declines sharply
• Sterlite's call option in HZL
• Reliance becomes full-fledged cell operator
• OVL to continue as flagship overseas oil co.
• Nicholas pact with Anna Varisty
• Residency Hotels' plans
• Thinksoft bags SBI order
• Roadshows by Western Union, India Post
• Stanchart, Central Bank sign pact
• New COO for Optimus
• Novartis gets EMR approval for Glivec
• Essar gets LoI for ILD services
• Stock Market Index
• Exchange rates
• Bullion rates

Copyright © 2003, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu